NCT07272772RecruitingPhase 2/3
Colon Cancer Diagnosis With FAPI-PET Imaging
Diagnostic Efficacy of 18F-FAPI-74 PET/CT in Patients With Colon Cancer
Source: ClinicalTrials.gov · Last updated 9 Dec 2025
Brief summary (registry, in English)
Whole body CT is the primary imaging method in staging and follow-up of colon cancer. Conventional PET-CT with 18F-labeled fluorodeoxyglucose (18F-FDG) has its limitations and has a secondary role in colon cancer protocols. A new PET tracer, fibroblast activation protein inhibitor (FAPI), targeting a protein that is overexpressed by cancer-associated fibroblasts presents a potential new PET imaging tool. The objective of this prospective study is to evaluate diagnostic efficacy of 18F-FAPI-74 PET/CT in patients with colon cancer. The aim is to evaluate the sensitivity and specificity of 18F-FAPI-74 in detection of local lymph node metastasis and distant metastasis in patient level in patients with colon cancer in primary staging and when suspected recurrence. 100 patients with colon cancer are enrolled and PET/CT studies are performed with the novel 18F-FAPI-74 tracer. The data will be collected between 2024-2026.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 26 Nov 2025
- Start date
- 9 Oct 2024
- Primary completion date
- Oct 2026
- Lead sponsor
- Turku University Hospital
- Diseases
- Colorectal cancer
- NCT number
- NCT07272772
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 100
- From 9 Oct 2024 to the primary completion date, Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Medical conditions prohibiting whole body PET-CT
Other
- Vulnerable study subjects such as described in Finnish law clinical studies (disabled, children, pregnant or breast-feeding women, prisoners) will not be included
- Patient is not able to understand purpose of study
Who the study is looking for
- Patients with primary colon cancer with suspicion of mesenteric lymph node metastases in computed tomography before primary cancer operation
- Patients with primary colon cancer with potentially curable metastases
- Patients with suspected metastasis or local recurrence in computed tomography and/or elevated carcinoembryonic antigen (CEA) in cancer surveillance
- WHO performance score 0-2
- Patient signs informed consent form after receiving written information
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Turku PET Centre, Turku University Hospital Coordinator of this site? Confirm its status | Turku | Finland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.